BeOne Medicines (NASDAQ:ONC) SVP Chan Henry Lee Sells 428 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 428 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $257.63, for a total value of $110,265.64. Following the transaction, the senior vice president owned 346,554 shares in the company, valued at $89,282,707.02. This represents a 0.12% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Chan Henry Lee also recently made the following trade(s):

• On Monday, June 8th, Chan Henry Lee sold 871 shares of BeOne Medicines stock. The stock was sold at an average price of $270.42, for a total value of $235,535.82.
• On Wednesday, May 13th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The stock was sold at an average price of $310.72, for a total value of $103,159.04.
• On Wednesday, April 8th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The stock was sold at an average price of $311.59, for a total value of $103,447.88.

BeOne Medicines Stock Performance

NASDAQ:ONC traded up $3.72 during mid-day trading on Monday, reaching $268.20. 351,440 shares of the stock were exchanged, compared to its average volume of 258,341. The company has a 50 day simple moving average of $298.56 and a 200-day simple moving average of $314.03. The stock has a market capitalization of $29.43 billion, a P/E ratio of 60.00 and a beta of 0.49. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $239.25 and a 1 year high of $385.22.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The firm had revenue of $1.51 billion for the quarter. Analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BeOne Medicines

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Capital International Investors increased its holdings in shares of BeOne Medicines by 1.3% in the 4th quarter. Capital International Investors now owns 5,113,866 shares of the company’s stock valued at $1,553,909,000 after purchasing an additional 67,808 shares in the last quarter. Siren L.L.C. boosted its holdings in BeOne Medicines by 1.4% during the fourth quarter. Siren L.L.C. now owns 500,000 shares of the company’s stock worth $151,905,000 after buying an additional 7,010 shares in the last quarter. Morgan Stanley boosted its holdings in BeOne Medicines by 23.9% during the fourth quarter. Morgan Stanley now owns 437,661 shares of the company’s stock worth $132,966,000 after buying an additional 84,367 shares in the last quarter. Bank of America Corp DE grew its position in BeOne Medicines by 7.0% during the first quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock worth $120,354,000 after buying an additional 26,441 shares during the period. Finally, Candriam S.C.A. increased its holdings in BeOne Medicines by 31.7% in the first quarter. Candriam S.C.A. now owns 259,731 shares of the company’s stock valued at $77,132,000 after buying an additional 62,470 shares in the last quarter. 48.55% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on ONC shares. Royal Bank Of Canada lifted their target price on BeOne Medicines from $425.00 to $436.00 and gave the company an “outperform” rating in a research note on Tuesday, June 2nd. Wall Street Zen upgraded BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Wells Fargo & Company started coverage on BeOne Medicines in a research note on Monday, May 4th. They issued an “overweight” rating and a $400.00 target price on the stock. Truist Financial reiterated a “buy” rating and issued a $413.00 target price (up from $411.00) on shares of BeOne Medicines in a research note on Thursday, May 7th. Finally, Jefferies Financial Group downgraded BeOne Medicines from a “buy” rating to a “hold” rating and lowered their target price for the company from $420.00 to $290.00 in a research note on Monday, March 16th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, BeOne Medicines presently has an average rating of “Moderate Buy” and an average price target of $390.00.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.